4th Annual Patient Recruitment and Retention in Clinical Trials

13th-15th October, 2008, Amsterdam
Patient recruitment and retention in clinical trials is the leading bottleneck in the new drug development pipeline. As the recruiting culture becomes more sophisticated and the forces affecting patient enrolment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrolment in clinical trials.

Achieving success in this environment requires trial sponsors to play a larger role in the recruitment process and to develop more collaborative working relationships with all stakeholders, including investigators and patients.

Key Speakers:

  • Astellas, UK, Vice President, Medical Affairs and Health Economics
  • AstraZeneca, Sweden, MD, PhD, Associate Professor
  • Baxter, Austria, Medical Director, Europe
  • Bristol-Myers Squibb, Russia, Clinical Operations Manager
  • Eli Lilly, USA, Director, Global Enrolment Optimization
  • Johnson & Johnson, USA, Director, Global Clinical Operations
  • GlaxoSmithKline, France, Executive Director, Medical Affairs and Clinical Development
  • Novo Nordisk, Denmark, Vice President, Clinical Operations, Trial Management
  • Lundbeck, Belgium, Director, International ClinicalResearch - Paediatric Neuro-Psychiatry
  • Pfizer, India, Head, Clinical Research
  • Roche, Turkey, Head of Clinical Trials
  • Sanofi-Aventis, Portugal, Clinical Trials Director
  • University Hospital Gasthuisberg Leuven, Belgium, Department of Paediatrics

Key topics:

  • The ½ Day pre-conference workshop will focus on retention strategies. Patient non-compliance can run as high as 80% and up to 40% of patients are lost to follow up in a clinical trial costing time and money.
  • Bringing Patient Recruitment into the 21st Century is looking into developing a foward thinking approach, considering public perception with respect to clinical trials, and looking into web-based recruitment
  • Key Components of a Clinical Trial focuses on issues such as communication between pharma, investigator and patient, protocol design and in-house training
  • Analysing Patient Populations addresses feasibility assessments, orphan indications and looks in to paediatric clinical trial challenges. This is followed by Recruiting and Retaining Patients in Emerging Markets where challenges and opportunities in regions such as the CIS, Turkey and India are examined.

Who should attend:
Vice Presidents and Directors of: Patient Recruitment, Patient Retention, Clinical Development, Clinical Operations, Clinical Trials, Clinical Marketing, Clinical Strategy, Clinical Project Management, Medical Affairs, Regulatory Affairs

For further information and registration, please visit:
http://www.jacobfleming.com/conferences/
life-science/4th-patient-recruitment-and-retention-in-clinical-trials

About Jacob Fleming Group
Jacob Fleming Group is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region, providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors. For more information, visit www.jacobfleming.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...